Excelsior Sciences Secures $95 Million to Revolutionize AI-Driven Small Molecule Drug Discovery
核心洞察
Excelsior Sciences (搜索) raised $95 million in Series A funding to develop proprietary "smart bloccs" technology that enables machines to perform chemistry and AI to guide closed-loop drug discovery.
The company's automated synthesis platform aims to accelerate drug discovery timelines by rapidly producing and testing compounds while generating rich data for AI algorithms.
The funding addresses pharmaceutical industry pressure to reshore drug discovery and manufacturing capabilities, with the industry committing over $250 billion to reduce strategic vulnerabilities.
Excelsior Sciences (搜索) announced it has secured $95 million in funding to advance its revolutionary approach to small molecule drug discovery, combining artificial intelligence with automated chemistry platforms. The financing includes a $70 million Series A round co-led by Deerfield Management (搜索), Khosla Ventures (搜索), and Sofinnova Partners (搜索), plus a $25 million grant from New York's Empire State Development (搜索).
The company has developed what it calls "smart bloccs"—automated synthesis-friendly chemical building blocks that enable iterative carbon-carbon bond formation. This proprietary technology represents a fundamental departure from traditional chemical synthesis approaches that have proven difficult to automate.
Addressing the Automation Challenge in Chemistry
Previous attempts to automate chemistry have failed because they replicated traditional artisanal approaches to chemical synthesis. Excelsior's innovation centers on creating a form of chemistry that machines can execute while providing AI systems with the data needed for closed-loop learning.
"Drug discovery and manufacturing are at a crossroads in the West. To stay competitive, we must discover and develop better medicines—faster," said Michael Foley, PhD, co-founder and CEO of Excelsior Sciences (搜索). "This can only be achieved through automated synthesis platforms capable of rapidly producing purified compounds and testing them across multiple assays simultaneously—generating the rich data AI needs to cut years off traditional discovery timelines."
The smart bloccs serve as a modular chemical "language" that allows AI to derive novel insights and guide discovery processes. This approach enables the seamless integration of discovery and scale-up chemistry, potentially transforming how pharmaceutical companies approach drug development.
Strategic Implications for Pharmaceutical Reshoring
Excelsior's launch addresses growing concerns about pharmaceutical supply chain vulnerabilities. The United States' overreliance on offshoring for drug discovery and manufacturing represents a major strategic weakness, with the pharmaceutical industry committing upwards of $250 billion to address these challenges.
"The idea that sparked Excelsior arose via the company-building relationship Deerfield cultivated with Dr. Marty Burke, whose lab at the University of Illinois discovered and patented the insights that power the smart blocc technology," said Jim Flynn, Managing Partner at Deerfield. "We view Excelsior's applications to drug discovery and manufacturing as transformational."
The company aims to make reshoring affordable for both discovery and manufacturing, providing what it terms "strategic immunity" to nations whose pharmaceutical supply chains are vulnerable to geopolitical disruptions.
Bridging AI Theory and Chemical Reality
Industry experts emphasize that Excelsior's technology addresses a critical gap in AI-driven drug discovery. While artificial intelligence can model molecular interactions in theory, translating these insights into actual chemical compounds has remained challenging.
"Everyone's talking about AI-designed drugs, but they cannot become a reality without scalable chemistry. Excelsior is the missing piece," said Edward Kliphuis, Partner at Sofinnova Partners (搜索). "They've built the right chemistry for the AI era, where design, synthesis, and testing happen in a closed loop."
Nessan Bermingham of Khosla Ventures (搜索) added, "Excelsior is closing the gap between what AI can model in theory and what chemistry can make in the real world. Being able to manufacture small molecules (搜索) this way opens the door to breakthroughs in new medicines and materials science."
Technology Platform and Applications
The smart bloccs platform creates molecular solutions from automated synthesis-friendly, function-infused, and AI-readable building blocks. These components function as tokens in a modular chemical language that enables AI to accelerate both discovery and manufacturing processes.
Small molecules (搜索), primarily built from carbon-carbon bonds, serve essential functions across multiple industries, including life-saving drugs, manufacturing materials, and agricultural products. While AI has shown potential to transform these fields, it requires the ability to rapidly synthesize and test new molecules to feed data-hungry algorithms.
Company Background and Future Plans
Excelsior Sciences (搜索) was spun out of Deerfield Management (搜索) and operates from custom-built laboratory space at Cure in New York City. The company was co-founded by Michael Foley, PhD, Marty Burke, MD, PhD, Bartosz Grzybowski, PhD, and Jana Jensen, PhD, MBA.
The Series A financing will support scaling of the smart bloccs platform and demonstration of its ability to revolutionize small molecule discovery and manufacturing. Excelsior also plans to invest in its internal pipeline and build partnerships across therapeutics and materials science sectors.
Other participants in the funding round include Cornucopian Capital, Eli Lilly and Company, Illinois Ventures, and MIT. Empire State Development (搜索) President Hope Knight noted that the investment exemplifies New York's role in attracting companies that redefine life sciences frontiers while establishing the state as a leader in AI-powered chemistry and advanced manufacturing.